1-14 of 14
Alain Mita
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B159: A first-in-human study of CDK9 inhibitor KB-0742 demonstrates evidence of tolerability and clinical activity

Miguel Villalona-Calero, Monica Mita, Alain Mita, Noah Federman, Drew Rasco, David Spigel, Jia Luo, Glenn J Hanna, Gregory M Cote, Richard E Cutler, Pavan Kumar, Crystal MacKenzie, Charles Lin, Jorge F DiMartino, Elizabeth A Olek, Brian Van Tine
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): B159.
https://doi.org/10.1158/1535-7163.TARG-23-B159
Published: 01 December 2023
View article titled, Abstract B159: A first-in-human study of CDK9 inhibitor KB-0742 demonstrates evidence of tolerability and clinical activity
Journal Articles

Abstract B001: A phase 1 trial of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies

Monica Mita, Alain Mita, Bartosz Chmielowski, Michael Postow, Erika Hamilton, Shubham Pant, Roger Waltzman, Eric Rowinsky, Michael Szarek, Foster Gonsalves, Isabel Kurth, Celia Andreu, Ilana Pollack, Daniel Mucida, Raissa Tanqueco, Sohail Tavazoie, Masoud Tavazoie
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): B001.
https://doi.org/10.1158/1535-7163.TARG-17-B001
Published: 01 January 2018
View article titled, Abstract B001: A phase 1 trial of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies
Journal Articles

Abstract A091: Phase 1 study of IAP inhibitor ASTX660 in adults with advanced cancers and lymphomas

Monica Mita, Patricia LoRusso, Michael S. Gordon, Aram Oganesian, Xiaoping Zhang, Roberta Ferraldeschi, Simone Jueliger, Harold N. Keer, Purvee Kumar, Chihche Lin, Edwin P. Rock, Alain Mita, Anthony W. Tolcher
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A091.
https://doi.org/10.1158/1535-7163.TARG-17-A091
Published: 01 January 2018
View article titled, Abstract A091: Phase 1 study of IAP inhibitor ASTX660 in adults with advanced cancers and lymphomas
Journal Articles

Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced Solid Tumors

Razelle Kurzrock, Nash Gabrail, Chandtip Chandhasin, Stacy Moulder, Carrie Smith, Andrew Brenner, Kamalesh Sankhala, Alain Mita, Kelly Elian, Danielle Bouchard, John Sarantopoulos
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (2): 308–316.
https://doi.org/10.1158/1535-7163.MCT-11-0566
Published: 08 February 2012
View article titled, Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced Solid Tumors
Open the PDF for Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced Solid Tumors in another window
Journal Articles

Abstract B55: A study of REOLYSIN in combination with gemcitabine in patients with advanced pancreatic adenocarcinoma.

Monica M. Mita, Yubao Wang, John Sarantopoulos, Sushma Vemulapalli, Benjamin George, Alain Mita, Mattew Coffey, George Gill, Devaligam Mahaligam
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B55.
https://doi.org/10.1158/1535-7163.TARG-11-B55
Published: 12 November 2011
View article titled, Abstract B55: A study of REOLYSIN in combination with gemcitabine in patients with advanced pancreatic adenocarcinoma.
Journal Articles

Abstract B191: Phase 1 pharmacokinetic (PK) assessments of ATI-1123, a novel human serum albumin-stabilized nanoparticle docetaxel liposomal formulation, in patients with advanced solid malignancies.

Devalingam Mahalingam, Alain Mita, Ahmed Kousba, Sushma Vemulapalli, Nicole Gallegos, Gavin Anderson, J. Charles, Jon M. Rogers, John Sarantopoulos, Monica Mita, Neil Senzer, John Nemunaitis
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B191.
https://doi.org/10.1158/1535-7163.TARG-11-B191
Published: 12 November 2011
View article titled, Abstract B191: Phase 1 pharmacokinetic (PK) assessments of ATI-1123, a novel human serum albumin-stabilized nanoparticle docetaxel liposomal formulation, in patients with advanced solid malignancies.
Journal Articles

Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients with Advanced Malignancies: A Phase I Clinical Trial

Apostolia-Maria Tsimberidou, Chris H.M. Takimoto, Stacy Moulder, Cynthia Uehara, Monica Mita, Alain Mita, Patrick Urban, Eugene Tan, Yanfeng Wang, David Vining, Razelle Kurzrock
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (1): 209–217.
https://doi.org/10.1158/1535-7163.MCT-10-0774
Published: 10 January 2011
View article titled, Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients with Advanced Malignancies: A Phase I Clinical Trial
Open the PDF for Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients with Advanced Malignancies: A Phase I Clinical Trial in another window
Journal Articles

Abstract C30: Phase 1/2 study of the vascular disrupting agent (VDA) plinabulin (NPI‐2358) combined with docetaxel in patients with non‐small cell lung cancer (NSCLC)

Rebecca Heist, Osvaldo Aren, Michael Millward, Paul Mainwaring, Alain Mita, Monica Mita, Lyudmila Bazhenova, Robert Blum, Jonathan Polikoff, Shirish Gadgeel, Chetan Deshmukh, G. Kenneth Llyod, Steven Reich, Matthew A. Spear
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): C30.
https://doi.org/10.1158/1535-7163.TARG-09-C30
Published: 10 December 2009
View article titled, Abstract C30: Phase 1/2 study of the vascular disrupting agent (VDA) plinabulin (NPI‐2358) combined with docetaxel in patients with non‐small cell lung cancer (NSCLC)
Journal Articles

Abstract B123: A phase I study of R1507, a human monoclonal antibody IGF‐1R (insulin‐like growth factor receptor) antagonist in patients with advanced solid tumors

Lia Gore, Joseph Aisner, Razelle Kurzrock, Cinara D. McCarthy, Erica Winter, Joseph Grippo, Stanley Frankel, Alain Mita
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B123.
https://doi.org/10.1158/1535-7163.TARG-09-B123
Published: 10 December 2009
View article titled, Abstract B123: A phase I study of R1507, a human monoclonal antibody IGF‐1R (insulin‐like growth factor receptor) antagonist in patients with advanced solid tumors
Journal Articles

Pharmacokinetic findings from the phase I study of Quarfloxin (CX-3543): a protein-rDNA quadruplex inhibitor, in patients with advanced solid tumors.

Kyriakos Papadopoulos, Alain Mita, Alejandro Ricart, David Hufnagel, Donald Northfelt, Daniel Von Hoff, Levan Darjania, John Lim, Claire Padgett, Robert Marschke
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): B93.
Published: 01 November 2007
View article titled, Pharmacokinetic findings from the phase I study of Quarfloxin (CX-3543): a protein-rDNA quadruplex inhibitor, in patients with advanced solid tumors.
Journal Articles

A phase I trial of the hemiasterlin analogue E7974 administered IV to patients with solid malignancies.

Alain Mita, Chris Takimoto, Naseem Zojwalla, Anthony Lucarelli, Romnee Clark, Monica Mita, Leslie Wood, Edgar Schuck, Ilya Krivelevich, Christopher Sweeney
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): A155.
Published: 01 November 2007
View article titled, A phase I trial of the hemiasterlin analogue E7974 administered IV to patients with solid malignancies.
Journal Articles

A phase I and pharmacokinetic study of a CanAg-targeted immunoconjugate, HuC242-DM4, in patients with CanAg-expressing solid tumors

Kamalesh Sankhala, Alain Mita, Alejandro Ricart, Monica Mita, Chia Lin, Leslie Wood, John Sarantopoulos, Chris Takimoto, Amita Patnaik, Albert Qin, Sybil Zildjian, Anthony Tolcher
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): B70.
Published: 01 November 2007
View article titled, A phase I and pharmacokinetic study of a CanAg-targeted immunoconjugate, HuC242-DM4, in patients with CanAg-expressing solid tumors
Journal Articles

A phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of XL820 administered orally daily (QD) or twice daily (BID) to patients (pts) with solid malignancies

Mark Stein, Salim Yazji, Jordi Rodon, Dale Miles, Pat O'Rourke, Kyriakas Papadopoulos, Alain Mita
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): B69.
Published: 01 November 2007
View article titled, A phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of XL820 administered orally daily (QD) or twice daily (BID) to patients (pts) with solid malignancies
Journal Articles

A Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of GTI2040 (GTI), a novel ribonucleotide reductase inhibitor in combination with gemcitabine (Gem) in adult patients (pts) with advanced solid tumors.

Chris Takimoto, Quincy Chu, Yun Yen, Patricia O'Rourke, Joshua Cooper, Sam Pardo, Anthony Tolcher, Amita Patnaik, Kyriakos Papadopoulos, Muralidhar Beeram, Alejandro Ricart, Chia-Chi Lin, Alain Mita, Emiliano Calvo, Igor Espinoza-Delgado, Jamie Zwiebel, John Sarantopoulos
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): C160.
Published: 01 November 2007
View article titled, A Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of GTI2040 (GTI), a novel ribonucleotide reductase inhibitor in combination with gemcitabine (Gem) in adult patients (pts) with advanced solid tumors.